Laduviglusib (GMP)

Overview

Laduviglusib (CHIR-99021) (GMP) is Laduviglusib ( HY-10182 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

Application

Products | Products > GMP Small Molecules | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Autophagy | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GSK-3 | Products > Signaling Pathways > Wnt | Products > Signaling Pathways > β-catenin | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-10182G
• CAS No.: 252917-06-9
• Molecular Formula: C22H18Cl2N8
• Molecular Weight: 465.34
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source